Log in

Cell MedX Stock Price, Forecast & Analysis (OTCMKTS:CMXC)

+0.01 (+2.04 %)
(As of 11/13/2019 08:53 AM ET)
Today's Range
Now: $0.50
50-Day Range
MA: $0.56
52-Week Range
Now: $0.50
Volume30,652 shs
Average Volume65,661 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Cell MedX Corp., a development stage company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, and high blood pressure. It also develops and manufactures eBalance technology that is in the research and development stage to manage diabetes mellitus and its complications. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada. Cell MedX Corp. is a subsidiary of Wisdom Homes of America, Inc.

Industry, Sector and Symbol

Industry Conglomerates
Current SymbolOTCMKTS:CMXC
Previous SymbolNASDAQ:CMXC



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive CMXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CMXC and its competitors with MarketBeat's FREE daily newsletter.

Cell MedX (OTCMKTS:CMXC) Frequently Asked Questions

What is Cell MedX's stock symbol?

Cell MedX trades on the OTCMKTS under the ticker symbol "CMXC."

Has Cell MedX been receiving favorable news coverage?

News articles about CMXC stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cell MedX earned a news impact score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Cell MedX.

Who are some of Cell MedX's key competitors?

What other stocks do shareholders of Cell MedX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cell MedX investors own include Linn Energy (LINEQ), Rapid7 (RPD), Globalstar (GSAT), Advanced Micro Devices (AMD), Motus GI (MOTS), KemPharm (KMPH), Kirkland's (KIRK), Frontier Communications (FTR), Citius Pharmaceuticals (CTXR) and Curis (CRIS).

Who are Cell MedX's key executives?

Cell MedX's management team includes the folowing people:
  • Mr. Frank E. McEnulty, CEO & Director (Age 63)
  • Ms. Yanika Silina C.M.A., CPA, CFO, Treasurer, Corp. Sec. & Director (Age 41)
  • Mr. Bradley S. Hargreaves, VP of Technology & Operations and Director (Age 60)

How do I buy shares of Cell MedX?

Shares of CMXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cell MedX's stock price today?

One share of CMXC stock can currently be purchased for approximately $0.50.

What is Cell MedX's official website?

The official website for Cell MedX is http://cellmedx.com/.

How can I contact Cell MedX?

Cell MedX's mailing address is 123 W Nye Ln Ste 446, CARSON CITY, NV 89706-0899, United States. The company can be reached via phone at +1-310-5089398.

MarketBeat Community Rating for Cell MedX (OTCMKTS CMXC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Cell MedX and other stocks. Vote "Outperform" if you believe CMXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel